Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$37.8M | -$68.6M | -$66.4M |
| Net income | -$36.3M | -$61.4M | -$63.2M |
| EPS (diluted) | -$9.73 | -$2.50 | -$2.19 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$33.4M | -$47.4M | -$51.8M |
| Capital expenditures | $470K | $2.08M | $24.0K |
| Free cash flow | -$33.9M | -$49.5M | -$51.8M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $82.5M | $168M | $176M |
| Total assets | $86.6M | $178M | $185M |
| Total liabilities | $16.8M | $26.1M | $33.5M |
| Long-term debt | $9.86M | $10.3M | $16.2M |
| Shareholders' equity | -$71.7M | $151M | $151M |
| Retained earnings | -$77.0M | -$138M | -$202M |
| Shares (wtd avg diluted) | 3.73M | 24.6M | 28.9M |
Every figure is extracted from Alto Neuroscience, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.